Doxycycline combined with Medroxyprogesterone

PreclinicalSmall molecule

Doxycycline combined with Medroxyprogesterone is one of 8 small molecule programs targeting Endometritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndometritisActive, not recruiting

EndometritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Endometritis

#DrugCompanyPhaseTrials

Acanya

Pfizer

Approved

—2

Ancef

BBaxter Healthcare Corporation

Approved

1 3

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—4

Rocephin

CConrado Roberto Hoffmann Filho

Approved

—5

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 6

Peridex

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Antibiotics

MMelinta Therapeutics, Inc.

Preclinical

1 8

Doxycycline combined with Medroxyprogesterone

FFang Wang

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

N/ARecruiting

Endometritis

NCT07488949

Clinical

Trials by Indication[1]

Endometritis1 trial

Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)

Recruiting·FFang Wang·N/A·NCT07488949·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Doxycycline combined with Medroxyprogesterone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxycycline combined with Medroxyprogesterone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxycycline combined with Medroxyprogesterone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fang Wang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFang Wang

Doxycycline combined with Medroxyprogesterone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Endometritis1 trial

References

Drug Info

Quick Facts

Related News